Page 2,185«..1020..2,1842,1852,1862,187..2,1902,200..»

Should Biogen Be Afraid of This Upstart?

Posted: Published on April 14th, 2015

Biogen (NASDAQ: BIIB) is a biotech Goliath that is best known for its dominant leadership in the treatment of multiple sclerosis. The company's top-selling MS drugs rack up sales of $7.9 billion per year, which makes it the market share leader in the $17 billion market for MS therapies. Although Biogen's MS franchise isn't likely to lose its luster anytime soon, a new drug in development at Receptos (NASDAQ: RCPT) could eventually pose a threat, so let's take a closer look. A huge market Spending on MS medicine per patient is estimated to total $52.36 per year, and that means MS is the second most costly specialty indication behind inflammatory conditions, such as rheumatoid arthritis. Spending on MS therapy is high in part because of the large number of people that are diagnosed with the disease, but also because the cost of MS medications can run into the tens of thousands of dollars per year. Globally, roughly 2.5 million people have MS, including more than 400,000 people in America and the average cost per MS prescription has been estimated to be $4,510 in 2014, which is up 9.2% from 2013. Over the past decade, one of the globe's top-selling therapies … Continue reading

Posted in MS Treatment | Comments Off on Should Biogen Be Afraid of This Upstart?

Horizon Pharma (HZNP) Stock Falls in After-Hours Today Following Public Share Offering Announcement

Posted: Published on April 14th, 2015

NEW YORK (TheStreet) --Horizon Pharma (HZNP - Get Report) shares are falling 2.6% to $27.75 in after-hours trading on Monday after the pharmaceutical company announced anunderwrittenpublic share offering. The company announced that it is offering to sell 12 million shares with the underwriters of the offering expected to be granted an additional 30 days to purchase an additional 15% ofthe ordinary shares in the public offering.Citigroup (C), Jefferies, Cowen (COWN) and Morgan Stanley (MS) are acting as joint book-running managers. On Friday Horizon announced that itsACTIMMUNE treatment fora degenerative neuro-muscular disorder known asFriedreich's ataxia (FA) received fast track designation from the FDA. Shares spiked 4% following the announcement. "We commend the FDA for granting Fast Track designation for ACTIMMUNE in Friedreich's ataxia to potentially help treat patients suffering from this debilitating disorder, for which there are no FDA approved treatments available. We look forward to continuing our ongoing clinical development program as we evaluate ACTIMMUNE in this patient population,"said CEO Timothy P. Walbert. TheStreet Ratings team rates HORIZON PHARMA PLC as a Sell with a ratings score of D. TheStreet Ratings Team has this to say about their recommendation: "We rate HORIZON PHARMA PLC (HZNP) a SELL. This is driven … Continue reading

Comments Off on Horizon Pharma (HZNP) Stock Falls in After-Hours Today Following Public Share Offering Announcement

Stem Cell Therapy Market worth $330 Million in 2020 – Video

Posted: Published on April 14th, 2015

Stem Cell Therapy Market worth $330 Million in 2020 This report studies the global stem cell therapy market over the forecast period of 2015 to 2020.The market is poised to grow at a CAGR of 39.5% from 2015 to 2020, to reach $330million by 2020. By: Healthcare Market Research … Continue reading

Comments Off on Stem Cell Therapy Market worth $330 Million in 2020 – Video

Gene therapy superior to half-matched transplant for 'bubble boy disease'

Posted: Published on April 14th, 2015

New research published online in Blood, the Journal of the American Society of Hematology (ASH), reports that children with "bubble boy disease" who undergo gene therapy have fewer infections and hospitalizations than those receiving stem cells from a partially matched donor. The research is the first to compare outcomes among children with the rare immune disorder -- also known as X-linked severe combined immunodeficiency (SCID-X1) -- receiving the two therapeutic approaches. Children with SCID-X1 are born with a genetic defect that prevents them from developing a normal immune system. Because they are prone to life-threatening infections, infants with SCID-X1 must be kept in a sterile, protective bubble and require extensive treatment for survival beyond infancy. Infants with SCID are most likely to survive if they receive a stem cell transplant from a fully matched donor -- typically a sibling -- a procedure that replaces an infant's diseased stem cells with healthy donor cells. Following a successful fully matched transplant, infants with SCID-X1 are able to produce their own immune cells for the first time. In the absence of a fully matched stem cell donor, infants with SCID-X1 may receive a transplant from a partial, or "half-matched," donor -- typically their … Continue reading

Comments Off on Gene therapy superior to half-matched transplant for 'bubble boy disease'

Nanoparticles at Specific Temperature Stimulate Antitumor Response

Posted: Published on April 14th, 2015

Contact Information Available for logged-in reporters only Newswise Seeking a way to stimulate antitumor responses via the immune system, Steven Fiering, PhD, of Norris Cotton Cancer Center at Dartmouth, has identified the precise temperature that results in a distinct body-wide antitumor immune response that resists metastatic disease. Fiering's team published the research in the paper "Local Hyperthermia Treatment of Tumors Induces CD8+ T Cell-Mediated Resistance Against Distal and Secondary Tumors," which appeared in Nanomedicine: Nanotechnology, Biology and Medicine. "Mild hyperthermia treatment of an identified tumor, prior to surgery to remove the tumor, shows excellent promise to strengthen the antitumor response and help stop metastatic disease," explained Fiering. Among the many options for cancer treatment pursued by science, immunotherapy is a contemporary focus. The immune system recognizes and usually eliminates small tumors, but other tumors become clinical problems and are known to block the antitumor tendencies with a natural system for immunosuppression. Recently, scientists have worked to learn how to reverse this tumor-mediated immunosuppression. In addition, phagocytes (key actors in immunosuppression and immunostimulation and that quickly take up nanoparticles) have provided options for new strategies. Fierings's studies were done in mice with a melanoma tumor model, and began with inserting iron … Continue reading

Comments Off on Nanoparticles at Specific Temperature Stimulate Antitumor Response

1 Dr Fayez Fouda Mesenchymal Stem Cells – Video

Posted: Published on April 14th, 2015

1 Dr Fayez Fouda Mesenchymal Stem Cells By: doaa gado … Continue reading

Posted in Mesenchymal Stem Cells | Comments Off on 1 Dr Fayez Fouda Mesenchymal Stem Cells – Video

You want me to do WHAT to fix my son's eczema?

Posted: Published on April 13th, 2015

JOSEFA PETE Last updatedMon Apr 13 03:00:00 UTC 2015 Gunnar Pippel 123RF Eczema, also known as dermatitis, affects one in three Australians and one in five New Zealanders at some stage in their lives Eczema in babies can be a hard diagnosis to face as a new mum, but that's exactly what I faced with my first son when he was just a few months old. He suffered from an all-over, ceaseless rash that consumed his happy spirit, while I chased my tail from one medical appointment to the next trying to ease his discomfort. Eczema, also known as dermatitis, affectsone in three Australiansand one in five New Zealandersat some stage in their lives. While eczema isn't contagious nor life threatening, the symptoms of this condition can have a significant impact on a person's quality of life. My son's quality of life was definitely consumed by his constant itch, red raw skin and a cycle of skin infections. It seemed that everything we tried worked for a little while, then the eczema flared up again. Our saving grace came from a nurse and I'm still thankful for her advice today although at the time, her tip was so confronting I … Continue reading

Posted in Eczema | Comments Off on You want me to do WHAT to fix my son's eczema?

BioBlast gets FDA fast track nod for muscle disease drug

Posted: Published on April 13th, 2015

Israeli pharmaceutical company BioBlast Pharma Ltd.(Nasdaq:ORPN) has announced that it has received US Food and Drug Administration (FDA) approval for fast track clinical trials of Cabaletta, its leading product, for treatment of oculopharyngeal muscular dystrophy (OPMD), a rare muscular disease. The fast track provides a company with better access to FDA staff in devising the trial procedures for products, with the aim of attaining more rapid approval when the trials results are submitted. Such approval is usually given only for diseases for which there is currently no treatment. Founded by Dr. Dalia Megiddo and Udi Gilboa, BioBlast has acquired a number of technologies for treating genetically caused diseases. All the diseases that BioBlast is attempting to treat are rare diseases, but all the technologies it has acquired are designed for treatment of several such diseases, so the company's technological potential is designed to suit the general market. Its leading product is for OPMD, a deadly disease with several dozen patients in Israel and several hundred in the US. A Phase II/III trials is currently taking place in Israel and China, with the US scheduled for inclusion soon. BioBlast's current market cap is $99 million. The company share has plummeted 37% … Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on BioBlast gets FDA fast track nod for muscle disease drug

Parents quizzed over bleach treatment for autism

Posted: Published on April 13th, 2015

Parents who gave their children bleach in the belief that it could cure them of autism are being questioned by garda. A number of people who have children with autism have been interviewed by detectives as part of a joint investigation by garda and the Health Products Regulatory Authority (HPRA) into the use of a controversial treatment being promoted in Ireland by an international cult. The substance, known as Miracle Mineral Solution (MMS), is an industrial-strength bleach which its advocates claim acts as a miracle cure for a number of medical conditions, including autism, asthma, Aids, malaria and ebola. Fiona OLeary, an Irish woman who has single-handedly mounted a campaign against a group led by Jim Humble a former Scientologist and self-styled archbishop of the Genesis II Church of Health and Healing said there is need for urgent legislation in Ireland to deter parents from subjecting their children to treatment with MMS. READ NEXT: 7 myths about autism debunked . A dentist and two nurses based in the west of Ireland are among a group of individuals who have also been questioned by garda about the sale of the product. Ms OLeary believes it is unlikely that any parents will … Continue reading

Comments Off on Parents quizzed over bleach treatment for autism

Both Physical Therapy, Mental Practice Important in Stroke Recovery

Posted: Published on April 13th, 2015

While recovering from a stroke, a patient should undergo both physical therapy and mental practice, according to a new study at Georgia State University in which researchers examined how the brains of stroke patients changed after treatment. Mental practice, also known as motor imagery, is the mental rehearsal of a motor action without actually doing the action. Physical therapy involves using repetitive, task-oriented training on the impaired body part. Both interventions are commonly used to improve impaired motor movement, coordination and balance following stroke. For the study, the researchers recruited 13 older stroke survivors as well as 17 young, healthy controls. Stroke participants were placed in two different groups for rehabilitation: mental practice only or both mental practice and physical therapy. The treatment was given within 14 to 51 days of the participants stroke and consisted of 60 total hours of rehabilitation. The effectiveness of each treatment was measured through functional magnetic resonance imaging (fMRI) scans on both the control group and on the stroke survivors before and after their treatment. During normal brain function, multiple cortical areas of the brain communicate with each other, but these interactions are disrupted after a stroke. The researchers looked into how a stroke … Continue reading

Comments Off on Both Physical Therapy, Mental Practice Important in Stroke Recovery

Page 2,185«..1020..2,1842,1852,1862,187..2,1902,200..»